Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director · President and CEO | August 12, 2026 | August 14, 2026 |
| Viridian Therapeutics, Inc.\DEMGEN · Entity 4316 | Director | May 21, 2020 | May 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edgewise Therapeutics, Inc.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,488 |
Ending reported balance
After 2026-08-12 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-08-12 · Exercise / conversion · Acquired 17,969 · Balance 48,584 Row 2 · 2026-08-12 · Exercise / conversion · Acquired 21,875 · Balance 70,459 Row 3 · 2026-08-12 · Sale · Disposed 8,782 · Balance 61,677 F1: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F2: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-08-12 · Sale · Disposed 8,276 · Balance 53,401 F1: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F3: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-08-12 · Sale · Disposed 913 · Balance 52,488 F1: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F4: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2034-08-12 | Direct | 35,938 |
Reported balance
After 2026-08-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-12 · Exercise / conversion · Disposed 17,969 · Balance 35,938 F5: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2035-08-12 | Direct | 65,625 |
Reported balance
After 2026-08-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-12 · Exercise / conversion · Disposed 21,875 · Balance 65,625 F6: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-08-12 | Direct | 100,000 |
Reported balance
After 2026-08-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-12 · Grant · Acquired 100,000 · Balance 100,000 F7: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2036-08-12 | Direct | 200,000 |
Reported balance
After 2026-08-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-12 · Grant · Acquired 200,000 · Balance 200,000 F8: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
F2: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
F6: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
F7: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
F8: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Viridian Therapeutics, Inc.\DE
Report date May 21, 2020 · Filed May 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2030-05-20 | Direct | 24,000 |
Reported balance
After 2020-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-21 · Grant · Acquired 24,000 · Balance 24,000 F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · derivative · entry 9 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2036-08-12 F8 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · derivative · entry 8 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-08-12 F7 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 21,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · derivative · entry 7 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,625 Underlying: Common Stock · 21,875 shares Expires 2035-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 17,969 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · derivative · entry 6 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,938 Underlying: Common Stock · 17,969 shares Expires 2034-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 913 | $44.33 | $40,473.29 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · nonDerivative · entry 5 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,488 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 8,276 | $43.66 | $361,315.26 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · nonDerivative · entry 4 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,401 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 8,782 | $43.64 | $383,253.51 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · nonDerivative · entry 3 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,677 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · nonDerivative · entry 2 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 17,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · nonDerivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 525,000 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001562180-25-005795 · primarydocument.xml · derivative · entry 9 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 525,000 shares Expires 2035-08-12 F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 87,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005795 · primarydocument.xml · derivative · entry 8 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2035-08-12 F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 17,968 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005795 · primarydocument.xml · derivative · entry 7 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,907 Underlying: Common Stock · 17,968 shares Expires 2034-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 7,972 | $13.39 | $106,764.21 |
DisclosureSEC source: 0001562180-25-005795 · primarydocument.xml · nonDerivative · entry 2 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,615 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 17,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005795 · primarydocument.xml · nonDerivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2025 Filed May 8, 2025 01:10 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 4,276 | $16.45 | $70,358.16 |
DisclosureSEC source: 0001562180-25-003658 · primarydocument.xml · nonDerivative · entry 2 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,619 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.07 to $16.84, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 8, 2025 01:10 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 10,417 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003658 · primarydocument.xml · derivative · entry 8 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,417 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 8, 2025 01:10 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003658 · primarydocument.xml · nonDerivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001562180-25-002293 · primarydocument.xml · derivative · entry 7 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,545 Underlying: Common Stock · 100 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 100 | $30.00 | $3,000.00 |
DisclosureSEC source: 0001562180-25-002293 · primarydocument.xml · nonDerivative · entry 2 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,478 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:32 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 100 | $0.18 | $18.00 |
DisclosureSEC source: 0001562180-25-002293 · primarydocument.xml · nonDerivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 900 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001562180-25-001025 · primarydocument.xml · derivative · entry 10 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,645 Underlying: Common Stock · 900 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 900 | $31.13 | $28,017.99 |
DisclosureSEC source: 0001562180-25-001025 · primarydocument.xml · nonDerivative · entry 4 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,478 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.1311, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 900 | $13.11 | $11,799.00 |
DisclosureSEC source: 0001562180-25-001025 · primarydocument.xml · nonDerivative · entry 3 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,636 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001562180-25-001025 · primarydocument.xml · derivative · entry 9 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,545 Underlying: Common Stock · 8,636 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 8,636 | $30.03 | $259,297.63 |
DisclosureSEC source: 0001562180-25-001025 · primarydocument.xml · nonDerivative · entry 2 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,478 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.14, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:38 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 8,636 | $0.18 | $1,554.48 |
DisclosureSEC source: 0001562180-25-001025 · primarydocument.xml · nonDerivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 71,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-006258 · primarydocument.xml · derivative · entry 2 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,875 Underlying: Common Stock · 71,875 shares Expires 2034-08-12 F2 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2024. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 431,250 | $0.00 Strike: $17.05 | $0.00 |
DisclosureSEC source: 0001562180-24-006258 · primarydocument.xml · derivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,250 Underlying: Common Stock · 431,250 shares Expires 2034-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on August 12, 2024, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 02, 2024 Filed May 3, 2024 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 3,152 | $18.91 | $59,604.32 |
DisclosureSEC source: 0001562180-24-003825 · primarydocument.xml · nonDerivative · entry 2 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,478 F1 · kind: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 10,417 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003825 · primarydocument.xml · derivative · entry 7 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,417 Underlying: Common Stock · 10,417 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 10,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003825 · primarydocument.xml · nonDerivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 23:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001562180-23-006451 · primarydocument.xml · derivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 02, 2023 Filed May 3, 2023 22:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 3,203 | $8.90 | $28,522.39 |
DisclosureSEC source: 0001562180-23-003918 · primarydocument.xml · nonDerivative · entry 2 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,213 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 10,416 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003918 · primarydocument.xml · derivative · entry 7 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,834 Underlying: Common Stock · 10,416 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: RSUs granted to the Reporting Person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:25 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 10,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003918 · primarydocument.xml · nonDerivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 21:41 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001562180-22-006025 · primarydocument.xml · derivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2032-08-08 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 31,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-003662 · primarydocument.xml · derivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2025-05-01 F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:09 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $16.38 | $0.00 |
DisclosureSEC source: 0001562180-21-005458 · primarydocument.xml · derivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 21, 2020 Filed May 22, 2020 21:16 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-20-031830 · doc4.xml · derivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 21:16 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-19-038570 · doc4.xml · derivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 20:44 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0001209191-18-039887 · doc4.xml · derivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-06-26 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 21:24 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $12.06 | $0.00 |
DisclosureSEC source: 0001209191-17-042574 · doc4.xml · derivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.